U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07056595) titled 'Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial' on June 30.
Brief Summary: : IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO. This finding supported the approval of finerenone by the U.S. Food and Drug Administration (FDA) for the treatment of chronic kidney disease (CKD). A subgroup analysis in the pooled FIDELITY tri...